Next, the team evaluated how accurately each dog could pick out a disease scent it was trained to detect among other smells.

HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and executed. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, HopeAI ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Radiation therapy may account for half of all new cancers among the growing population of childhood cancer survivors, according to a study published Aug. 11 in the Journal of Clinical Oncology. With ...

American Cancer Society Cancer Action Network, American Cancer Society, CAMPAIGN, Congress ,funding for cancer research ...

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Cervical cancer is highly preventable with routine screening. To provide people with a cervix a comfortable and private ...

American Oncology Network (AON), one of the fastest-growing networks of community-based oncology practices in the United States, today announced the ...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...